$HHSE_NEWS:..Worldwide-Streaming-Revenues for WILDFIRE

New Post Public Reply Private Reply Replies (0) Message Board
HHSErocks WALL STREET SIGNALS #146081
71
$HHSE_NEWS:..Worldwide-Streaming-Revenues for WILDFIRE Drive-Record-Results for Hannover-House
 
Earnings Announcement
 
OTC Disclosure & News Service | 08/14/2026
 
https://www.otcmarkets.com/stock/HHSE/news/Wo...?id=531842

(Click on link to view Tabulated Revenues)

Q2 Revenues Jump and Profits Grow 16-X; HHSE management calls it the beginning of a major resurgence for the 33-year-old independent media company.

Los Angeles, California - A fifty-year-old hit song has delivered the first bona-fide audience hit for indie distributor Hannover House, Inc. (OTC: HHSE). "Wildfire: The Legend of the Cherokee Ghost Horse" – a family appeal feature film based on the number 1 worldwide hit song by Michael Martin Murphey – has connected with streaming audiences worldwide, and positively impacted the company's revenues. Sales for the quarter ending June 30, 2026 jumped to $485,290 as compared to $99,730 for the same quarter last year; while bottom line profits surged to $400,810, an increase of more than 16-X over profits of $25,484 for the June 30, 2025 period.

"This is just the beginning of a new revenue cycle for Hannover House," said Eric Parkinson, C.E.O. "Viewership of the film through streaming platforms worldwide continues to grow, and should result in consistent growth over the next few quarters. While we’re very happy with the current activity for 'Wildfire', we believe that the higher stature productions now underway for Hannover House will ultimately return many millions more in revenue."

Current productions for Hannover House include the Oscar-caliber historic epic, "The 17N Conspiracy," based on the true story of the democratic revolution in Greece in the 1970s. This high-profile production will be Hannover’s locomotive entry for revenue results and awards-consideration in 2027. Other productions for the company include the historic western, "Indian Territory," and the anthology of Native American-themed short films called "Native Fables." As a follow-up to his 2025 horror-thriller, "Unholy Song," writer-director Arthur G. Night has partnered with Hannover House on an ambitious Christmas thriller called "Jolly," which is now in post-production and set for a theatrical and streaming launch later this year. The company is also in pre-production for a $22-million sci-fi adventure to shoot in Malta called "Tempus Porta."

In addition to Hannover House facilitated feature productions, the company will also be releasing several acquisitions to theatres and streaming. "Sinatra: Eternity" was acquired at Cannes from Crisis Cinema and chronicles the life and career of Frank Sinatra as prompted by a writer interviewing the legend. "Sexbot" is a hilarious comedy for our current technological age, from writer-director Ash Baron-Cohen. Hannover House plans a major theatrical campaign for the film around Valentine's Day, 2027.

The company will also promote the release of a political marketing book from best-selling author Barr McClellan starting next week. "American Manifesto: The Winning Campaign Strategies of President Donald J. Trump" goes behind the scenes and deep into the operations of Team Trump in 2024, as they devised and implemented a marketing campaign to emphasize voter hot-button issues, and to fuel the Democratic party leaders into self-sabotage by taking-the-bait on unpopular wedge issues. McClellan feels that the book is a must-read for any campaign strategist, as the information is useful for what to do, and what not to do, for current and upcoming political campaigns.

"Our current results prove the viability of our business strategy," said Parkinson. "Our upcoming release slate will take us to the next level in terms of revenues, assets and profitability. We are thankful for the loyal support of our shareholders, and are happy that we are finally delivering on the results that will fuel a major growth in our stock value," he concluded.

Hannover House was formed in 1993 as Truman Press, Inc., a specialty book publisher. Eric Parkinson purchased the company in 2002 and added DVDs to the company's product offerings. Within just three years, Hannover House grew into a top ten DVD supplier for Walmart Stores, Inc., with significant market presence also earned through Target, Best Buys and thousands of other retail outlets in North America. With the market transition away from physical goods like DVD and BluRay products, Hannover House began placing titles with streaming services, and ultimately, found a working structure for independent products to follow a premium V.O.D. launch window, followed by wide distribution through Advertiser-supported V.O.D. providers (including Tubi and Roku). Higher profile products have also benefitted from the visibility and momentum generated from major market theatrical release windows, which Hannover House expects to become the leading revenue source for the company in 2027 for major features such as "The 17N Conspiracy."

Hannover House also recently resurrected the Hemdale releasing brand, a company for which CEO Eric Parkinson was a principal for many years. Hemdale was one of the most prolific producers and distributors of quality, independent movies from 1967 until 1996, when the impressive film library was sold to MGM-UA. Hit films for Hemdale include "Terminator," "Hoosiers," "Criminal Law", "Impromptu," and Best Picture Academy Award winners "Platoon," and "The Last Emperor." Hemdale also set multiple sales records for home video releases, including chart-topping results for the animated features "Magic Voyage," "The Princess & The Goblin" and "Little Nemo: Adventures In Slumberland." Other Hemdale titles proved to be hugely popular rental videos, including "Savage Land," "Future Shock" and "Grizzly Mountain," all three of which were written and produced by Eric Parkinson. With Hannover's new involvement in higher-profile features, Parkinson said that the timing to resurrect the Hemdale releasing brand felt right.

"We finally have Oscar-caliber projects again," said Parkinson. "Producing and releasing these films under the Hemdale brand is an appropriate nod to the legacy of quality and socially-meritorious content that Hemdale established."

For more information, contact: Alessandra Di Caterino, ADC@Hemdale.us, 332-271-0217
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Antheia Secures $80M for Critical Medicine Onshoring

Updated Category News Views 19

Antheia's Bold Move to Onshore Medicine Production Folks, when it comes to pharmaceuticals, it's about time someone started serious about keeping things closer to home. Antheia just landed a huge $80 million conditional commitment from the U.S. Department of War's Office of Strategic Capital. The fine print? This isn't just about building business—it's a play to secure...

Continue Reading
Faith and Resilience in China: The Legacy of the Long March

Updated Category News Views 14

History's got chapters that stick with you, and the Long March is one of those stories that shake you to your core. It all started one October evening in 1934, when more than 86,000 soldiers from the Red Army found themselves on the banks of the Yudu River. It was a scene straight out of a novel: 800-odd boats held together with coffin boards and timber beams, all set to...

Continue Reading
AEVEX Faces 48-Hour Deadline for Investor Class Action

Updated Category News Views 11

Clock Ticking on AEVEX Lawsuit Participation Ah, the twists and turns of the stock market! AEVEX Corp. (NYSE: AVEX) finds itself knee-deep in a class action lawsuit, and investors have a mere 48 hours left to make their stand as the lead plaintiff. This legal saga stems from the company's April 2026 IPO and spills into the muddy waters of securities law violations....

Continue Reading
ASTS Faces a Legal Countdown – Investors Take Note

Updated Category News Views 10

AST SpaceMobile's Legal Tangle AST SpaceMobile, Inc. (NASDAQ:ASTS) finds itself neck-deep in legal quagmire, with a class action lawsuit looming large. Investors who snapped up ASTS securities between March 4, 2025, and July 15, 2026, have until November 13, 2026, to reckon their grievances before the courts. This is no joke, folks. If you've lost dough because of shaky...

Continue Reading
Tomorrowland's Shanghai Return: An Electri-Lifesaver

Updated Category News Views 20

You know, every now and then, it's worth stepping out of the stock frenzy and diving into something as electrifying and far from the trading floor as Tomorrowland's latest Shanghai rendezvous. This ain't just any festival; it's the kind of hype that packs a punch—and frankly, it's a wild ride seeing such a spectacle set up shop in China, and sell out to boot. Partnering...

Continue Reading
UEG's New Advisory Board: Elevating Patient Voices

Updated Category News Views 17

Breaking Ground with Patient Representation Today's not-so-sunny forecast from Barcelona wasn't about the weather. United European Gastroenterology (UEG) rolled out its shiny new Patient Representatives Advisory Board (PRAB) during UEG Week 2026. This isn't just another committee on a never-ending list—it's a serious platform aimed at turning patient murmurs into a...

Continue Reading
Lundbeck's Board Leadership Transitions into New Era

Updated Category News Views 8

A Fresh Chapter for Lundbeck's Board Leadership Lundbeck is sparking some fresh boardroom energy, and it's not just business as usual. Dorothea Wenzel, who's been steering the ship, is stepping down come 2027—AGM in sight. Now, in swings Lars Fruergaard Jørgensen, ready to grab the wheel. Yeah, we've got some seasoned pharma muscles flexing here. The Before and After:...

Continue Reading

Top 5 Most Recently Viewed Articles

Sera Prognostics to Showcase Innovations at RBC Healthcare Event

Updated Category News Views 112

Sera Prognostics to Showcase Innovations at RBC Healthcare Event Sera Prognostics Inc., known as The Pregnancy Company (NASDAQ: SERA), is focused on enhancing maternal and neonatal health through innovative pregnancy biomarker information. The company has recently announced its participation at an important healthcare event, highlighting its ongoing commitment to improve...

Continue Reading
Unlocking AI Potential: Insights from Netcracker CEO Andrew Feinberg

Updated Category News Views 268

Exciting Keynote at GITEX Global 2024 Netcracker Technology is buzzing with excitement as Andrew Feinberg, the Chairman and CEO, prepares for a pivotal keynote presentation at one of the largest tech events in the world, GITEX Global 2024. This annual technology conference draws innovators, industry leaders, and enthusiasts keen on understanding the future of technology....

Continue Reading
Adherium Empowers COPD and Asthma Management with iCARE Study

Updated Category News Views 147

Adherium's Transformative iCARE Study Results The innovative strides made by Adherium Limited (ASX:ADR) in respiratory health have shown promising outcomes as seen in the iCARE study. This study investigated the effectiveness of their Hailie® Smartinhaler® technology in improving adherence among patients suffering from chronic obstructive pulmonary disease (COPD) and...

Continue Reading
Medius Highlights Impending Finance Challenges Post AI Launch

Updated Category News Views 243

AI Fraud Concerns Elevate in the Finance Sector Medius has unveiled alarming findings indicating that nearly one in three finance professionals are unable to spot AI-generated fake receipts. This revelation surfaces amidst rising fears of fraud escalation following the recent launch of GPT-5.0. With the capabilities of AI continuously improving, finance teams must prepare...

Continue Reading
TD Cowen Sustainably Endorses Abbott Labs with Robust Price Target

Updated Category News Views 59

TD Cowen Affirms Buy Rating on Abbott Laboratories TD Cowen has reaffirmed its Buy rating on Abbott Laboratories (NYSE: ABT), maintaining a price target of $130.00 for the healthcare company's shares. This positive stance hinges on expectations that Abbott's upcoming third-quarter results will either meet or surpass current market predictions, allowing the company to...

Continue Reading